| Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates | 11/07 18:36 | zacks.com |
| Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results | 11/07 16:01 | globenewswire.com |
| Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences | 11/04 07:00 | globenewswire.com |
| Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting | 10/15 07:00 | globenewswire.com |
| Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength? | 10/09 04:50 | zacks.com |
| Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates | 08/08 18:25 | zacks.com |
| Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results | 08/08 16:01 | globenewswire.com |
| Dianthus (DNTH) Gains 18% in the Past Month: Here's Why | 07/08 12:11 | zacks.com |
| Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN) | 06/28 11:30 | globenewswire.com |
| Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN) | 06/12 07:00 | globenewswire.com |